On 22 April 2025, Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) announced that it will be conducting a placement of 10,810,811 fully paid ordinary shares in the Company at an issue price of $0.37 per Share to sophisticated, institutional and professional investors, raising approximately $4 million.
TruScreen Group Limited (ASX:TRU) (NZE:TRU) advises that it has re-entered the Indian subcontinent with the appointment of India medical products distributor Renovate Biologicals Pvt Ltd to distribute its unique AI enabled TruScreen cervical cancer screening system in India.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics is pleased to provide the following update on its business activities for the three months to 31 March 2025 and subsequent to the period end.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) is pleased to announce that it has received firm commitments from new and existing investors and Directors and Key Management Personnel for a non-underwritten placement of approximately 12.1 million new fully paid ordinary shares at $0.37 per New Share.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, will give an investor briefing at the Alpha ex-100 Conference hosted by Morgan Stanley in Sydney today.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) is pleased to announce the formation of its Clinical Advisory Board for its world-first diagnostic blood test to identify esophageal cancer, specifically esophageal adenocarcinoma, PromarkerEso.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics has secured new intellectual property protection following the grant of a patent in Australia for the platform technology which precisely measures levels of oxidative stress.
